Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
International Society for Gastrointestinal Hereditary Tumours |
RCV000076424 | SCV000107452 | likely pathogenic | Lynch syndrome | 2019-06-21 | reviewed by expert panel | curation | Interrupts canonical donor splice site |
Color Diagnostics, |
RCV003584546 | SCV004356727 | likely pathogenic | Hereditary cancer-predisposing syndrome | 2022-06-07 | criteria provided, single submitter | clinical testing | This variant causes a G to C nucleotide substitution at the +1 position of intron 13 of the MSH2 gene. Splice site prediction tools predict that this variant may have a significant impact on RNA splicing. This alteration has been reported to result in out-of-frame skipping of exon 13 (PMID: 11879922, 16451135), creating a frameshift and premature translation stop signal and expected to result in an absent or non-functional protein product. This variant has been observed in an individual with colorectal cancer that exhibited microsatellite instability and loss of MLH1 and MSH2 proteins by immunohistochemistry analyses (PMID: 17189986), and in families affected by hereditary non-polyposis colorectal cancer (PMID: 11879922, 16451135). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Different variants affecting the same splice donor site, c.2210+1G>T and c.2210+1G>A, are known to be disease-causing (ClinVar variation ID: 820897, 90921). Loss of MSH2 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Likely Pathogenic. |